Introduction {#Sec1}
============

According to Quality Outcomes Framework (QOF) of Diabetes UK, an estimated 3.7 million patients in the UK are currently living with diabetes \[[@CR1]\], and this number is predicted to increase in the future \[[@CR2]\]. These findings will have implications on the burden of diabetes complications (heart disease, stroke, visual impairment, chronic kidney disease, peripheral vascular disease) that can reduce the quality of life and shorten life expectancy \[[@CR3]\]. Such complications have been strongly associated with increasing glycated hemoglobin (HbA1c) levels among patients with type 2 diabetes (T2D) \[[@CR4]\].

As many as half of those treated for T2D do not achieve the specified targets for HbA1c \[[@CR5], [@CR6]\] and consequently require therapy intensification \[[@CR7]\]. In line with American Diabetes Association (ADA) guidelines \[[@CR8]\], the National Institute for Health and Care Excellence (NICE) guidelines for management of T2D in adults recommend that HbA1c levels be measured at 3- to 6-month intervals---as appropriate---following therapy initiation. NICE recommends that patients' HbA1c targets be adjusted according to risk of hypoglycemia, with intensification being considered if the HbA1c level rises above 7.5% (58 mmol/mol) \[[@CR7]\]. If control is not achieved with sequential dual oral therapy, adding on a third non-insulin therapy (triple therapy) or any insulin-containing therapy combination is recommended \[[@CR7]\]. NICE also recommends rescue therapy with insulin or a sulfonylurea at any phase if patients are symptomatically hyperglycemic \[[@CR7]\]. For comparison, the ADA HbA1c target is \< 7.0% (53 mmol/mol) for most nonpregnant adults, with intensification strategies depending on various patient factors. Additionally, if HbA1c is \> 10.0% or the hyperglycemia is symptomatic, ADA guidelines highlight that insulin can be considered immediately \[[@CR8]\].

Despite clear NICE recommendations, clinical control of HbA1c levels in patients with diabetes in the UK often remains suboptimal (≥ 7.5% \[≥ 58 mmol/mol\]), and therapeutic inertia may exist for prolonged periods of time \[[@CR9]--[@CR12]\]. Successful glycemic control has been shown to reduce the risk of T2D-related mortality, myocardial infarction, and microvascular complications \[[@CR13]\]. However, little research has been undertaken to assist healthcare providers in judging the appropriate timing for therapy intensification in clinical practice.

The aim of this retrospective observational cohort study was to evaluate the effect of therapy intensification (vs. no intensification) on HbA1c levels at 6 and 12 months in patients with T2D suboptimally controlled on basal insulin (BI) and to evaluate the proportion of patients attaining HbA1c targets. The findings will provide information to healthcare providers on the optimal timing for therapy intensification for patients with T2D whose glycemic control remains suboptimal on BI.

Methods {#Sec2}
=======

Study Design and Data Source {#Sec3}
----------------------------

The Health Improvement Network (THIN) database was used in this retrospective observational cohort analysis. This is a UK primary care database of pseudonymized electronic medical records from 3.1 million actively registered patients in 390 general practitioner practices as of January 2017. THIN was considered to be a suitable data source for this study as T2D is managed in the primary care setting in the UK \[[@CR7]\], and the prevalence of T2D in this database is comparable with national estimates for the UK \[[@CR14]\]. The study protocol was approved by the THIN Scientific Review Committee under submission 17THIN068.

Study Cohorts {#Sec4}
-------------

Patients aged ≥ 18 years with T2D and suboptimal  glycemic control who had been prescribed BI between 1 January 2005 and 16 May 2017 were identified from the THIN database. The date of the first incidence of suboptimally controlled HbA1c was recorded as index 1 for each patient. For patients who intensified therapy (termed 'intensifiers'), the date of therapy intensification was recorded as index 2.

A control cohort of patients with suboptimally controlled HbA1c who did not intensify therapy (termed 'non-intensifiers') were matched on a 1:1 basis with intensifiers. Exact matching was performed between the two groups according to: age group at baseline (as per Table [1](#Tab1){ref-type="table"}); sex; baseline HbA1c category (7--7.9, 8--8.9, 9--9.9, 10--10.9, 11--11.9, ≥ 12% \[53--63, 64--74, 75--85, 86--96, 97--107, ≥ 108 mmol/mol, respectively\]); number of unique prescribed antihyperglycemia drugs at index 1 (1, 2, or ≥ 3); and time from first T2D diagnosis to index 1.

Therapy intensification was defined as the addition of a glucagon-like peptide-1 receptor agonist (GLP-1 RA) or a rapid-acting insulin (RAI) to current treatment during the 12 months following index 1. Patients without evidence of such therapy additions were classified as non-intensifiers. For non-intensifiers, a pseudo date within 12 months of index 1 was assigned as index 2. This date was chosen so that the duration from index 1 to index 2 was the same as that of the matching intensified patient.

Baseline HbA1c was the HbA1c measurement at index 1 (Fig. [1](#Fig1){ref-type="fig"}). Suboptimal HbA1c control was defined as HbA1c \> 7.5% (\> 58 mmol/mol) for patients not at high risk of hypoglycemia and as HbA1c \> 8.0% (\> 64 mmol/mol) for those at high risk of hypoglycemia; HbA1c targets for the groups were ≤ 7.5 and ≤ 8.0%, respectively. High-risk patients had a history of hypoglycemic coma pre index 1 or they were aged \> 65 years with ≥ 1 of the following conditions prior to index 1: congestive heart disease, non-hemorrhagic stroke, myocardial infarction/coronary heart disease, peripheral vascular disease, or renal dysfunction.Fig. 1Study design. *HbA1c* Glycated hemoglobin, *THIN* The Health Improvement Network

Patients had ≥ 180 days of clinical data prior to index 1 (baseline) and ≥ 365 days of clinical data after index 2 (follow-up). Patients were excluded if the HbA1c level improved to below the target level between index 1 and index 2, if they became pregnant during the study period, or if they had received therapy intensification in the baseline period prior to index 1.

Outcomes of Interest {#Sec5}
--------------------

Primary outcomes were: (1) changes in HbA1c at 6 months and 12 months post index 2, and (2) the proportion of patients achieving target HbA1c at 6 and 12 months post index 2.

Other outcomes of interest included comparisons of therapy adherence (proportion of days covered \[PDC\]) and persistence (time to discontinuation) pre index 1 (baseline) and post index 2, and assessment of the impact of delay in initiation of therapy intensification.

Statistical Analysis {#Sec6}
--------------------

The difference in HbA1c change between the two groups post index 2 was calculated using summary statistics and unadjusted/adjusted mixed model repeated measure (MMRM) estimates. Adjusted logistic regression was used to compare the proportion of patients achieving the target HbA1c during the 12 months post index 2. A Cox proportional hazards model was used to describe time to target HbA1c attainment (presented using a Kaplan--Meier curve). As a Bonferroni adjustment was applied to all *P* values based on 100 tests conducted, *P* \< 0.0005 was considered to be significant.

BI adherence at baseline was defined as the PDC in the 180 days prior to index 1, calculated as the days supplied divided by the total number of follow-up days, excluding any overlapping days supplied. Days supplied was taken either directly from patients' medical records or calculated based on quantity supplied and daily dose. The formula defined by Basak et al. \[[@CR15]\] was used to account for overlapping combinations of prescriptions. Adherence to intensification therapy post index 2 was measured by the PDC for the intensification therapy during a 365-day follow-up period and included the use of any drug qualifying as therapy intensification at index 2. The PDC is commonly used to measure insulin adherence in database studies \[[@CR16]\]. In about 63% of patients, the insulin dose was derived from THIN and, in about 37% of patients, it was imputed based on data available. Adherence post index 2 was not measured for the non-intensifiers as they did not receive an intensification therapy.

As pharmacy claims data were not available, persistence was defined as a period free of any gap in therapy of \> 60 days post index 2 (gaps of ≤ 60 days were allowed). Gaps in treatment were calculated based on the time between the calculated end date for a prescription (based on start date and recorded or derived duration) and the start date of the next prescription. If multiple persistent periods were observed post index 2, the first period was used.

Delay in therapy intensification was measured in days from index 1 to index 2 for patients who intensified at any point during the study (i.e., all intensifiers, plus a subset of non-intensifiers who intensified therapy later than 12 months post index 1).

Results {#Sec7}
=======

Baseline Characteristics {#Sec8}
------------------------

We identified 1342 BI users (*n* = 646 intensifiers, *n* = 696 non-intensifiers) from the THIN database who met the study inclusion criteria (Fig. [2](#Fig2){ref-type="fig"}). Baseline characteristics are shown in Table [1](#Tab1){ref-type="table"}. Mean baseline HbA1c was similar in the two groups: 9.38% (standard deviation \[SD\] 1.45\] and 9.40% (SD 1.57), respectively. Overall, 90% of patients were assigned a target HbA1c of 7.5% at baseline, with the reminder being assigned a target HbA1c of 8.0%.Table 1Baseline demographics and characteristicsCharacteristicOverall (*n* = 1342)Intensified therapyNot intensified therapy (*n* = 696)GLP-1 RA (*n* = 55)RAI (*n* = 591)Total (*n* = 646)Mean age, years (SD)58.7 (13.1)55.1 (10.1)58.6 (13.1)58.3 (12.9)59.0 (13.3)Age range, years, *n* (%) 18--44198 (14.8)8 (14.5)86 (14.6)94 (14.6)104 (14.9) 45--54308 (23.0)18 (32.7)132 (22.3)150 (23.2)158 (22.7) 55--64391 (29.1)21 (38.2)169 (28.6)190 (29.4)201 (28.9) ≥ 65445 (33.2)8 (14.5)204 (34.5)212 (32.8)233 (33.5)Male,*n* (%)718 (53.5)27 (49.1)316 (53.5)343 (53.1)375 (53.9)Mean HbA1c,  % (SD)9.39 (1.52)9.37 (1.31)9.38 (1.47)9.38 (1.45)9.40 (1.57)HbA1c category, *n* (%) 7.5 to \< 9.0% (58-- \< 75 mmol/mol)631 (47.0)24 (43.6)281 (47.5)305 (47.2)326 (46.8) 9.0 to \< 10.0% (75-- \< 86 mmol/mol)312 (23.2)15 (27.3)136 (23.0)151 (23.4)161 (23.1) ≥ 10.0% (≥ 86 mmol/mol)399 (29.7)16 (29.1)174 (29.4)190 (29.4)209 (30.0)Duration of diabetes, *n* (%) \< 5 years107 (8.0)--^a^51 (8.6)51 (7.9)56 (8.0) 5 to \< 10 years433 (32.3)--^a^200 (33.8)200 (31.0)233 (33.5) ≥ 10 years780 (58.1)33 (60.0)340 (57.5)373 (57.7)407 (58.5)Number of antihyperglycemia drugs, *n* (%) 1589 (43.9)--^a^277 (46.9)277 (42.9)312 (44.8) 2577 (43.0)29 (52.7)254 (43.0)283 (43.8)294 (42.2) ≥ 3150 (11.2)--^a^60 (10.2)60 (9.3)90 (12.9)Mean weight, kg (SD)90.3 (21.3)110.8 (25.8)88.0 (20.2)90.2 (21.8)90.4 (20.9)Mean BMI, kg/m^2^ (SD)32.0 (7.3)39.2 (8.6)31.0 (6.7)31.8 (7.3)32.1 (7.4)Comorbidities, *n* (%) Hypertension137 (10.2)--^a^63 (10.7)63 (9.8)74 (10.6) Dyslipidemia23 (1.7)--^a^8 (1.4)8 (1.2)15 (2.2) Obesity (including baseline BMI \> 30 kg/m^2^) 500 (37.3)40 (72.7)198 (33.5)238 (36.8)262 (37.6)*BMI* body mass index, *GLP-1 RA* glucagon-like peptide-1 receptor agonist,*HbA1c* glycated hemoglobin, *RAI* rapid-acting insulin, *SD* standard deviation^a^Indicates patient numbers \< 6 for whom data were not provided in order to maintain anonymityFig. 2Patient disposition. *BI* basal insulin, *GLP*-*1 RA* glucagon-like peptide-1 receptor agonist, *RAI* rapid-acting insulin, *T2D* type 2 diabetes

Among the intensifiers, 91.5% added a RAI and 8.5% added a GLP-1 RA to their BI therapy. Mean weight, body mass index (BMI), and prevalence of obesity were all higher in the subgroup of intensifiers who added a GLP-1 RA than in the subgroup of non-intensifiers. This observation is consistent with NICE guideline recommendations that adults with T2D who have a BMI ≥ 35 kg/m^2^ should receive a GLP-1 RA \[[@CR7]\].

Glycemic Control {#Sec9}
----------------

Improvement in HbA1c at 6 months was substantially greater for intensifiers (mean \[SD\] − 0.81% \[1.7%\]) than for non-intensifiers (− 0.35% \[1.7%\]) (Fig. [3](#Fig3){ref-type="fig"}a). HbA1c change at 12 months was also greater for intensifiers (mean \[SD\] − 0.81% \[2.0%\]) versus non-intensifiers (− 0.49% \[2.1%\]) (Fig. [3](#Fig3){ref-type="fig"}b), but without additional gain/improvement as compared with the 6-month assessment.Fig. 3Change in HbA1c from baseline during the follow-up for intensifiers and non-intensifiers. **a** At 6 months, **b** at 12 months

The unadjusted MMRM estimate for therapy difference for HbA1c change was − 0.37% (95% confidence interval \[CI\] − 0.55%, − 0.18%; *P* = 0.0002) at 6 months, and − 0.33% (95% CI − 0.52%, --0.14%; *P* = 0.0007) at 12 months. The adjusted MMRM estimate for therapy difference for HbA1c change was − 0.41% (95% CI − 0.64%, − 0.17%; *P* = 0.0006) at 6 months and − 0.32% (95% CI − 0.55%, − 0.08%; *P* = 0.0077) at 12 months.

A higher proportion of intensifiers versus non-intensifiers achieved target HbA1c at 6 months (25.1% vs. 18.8%, respectively; *P* \< 0.0001 by logistic regression) and at 12 months (33.4% vs. 28.2%, respectively; *P* \< 0.0001 by logistic regression). At 12 months, the target HbA1c was achieved by a higher proportion of intensifiers receiving GLP-1 RA versus those receiving RAI (45.5% vs. 32.3%, respectively), although the proportions were low.

A Kaplan--Meier analysis showed a numerically greater probability of HbA1c target achievement for intensifiers at 6 months that was maintained at 12 months (Fig. [4](#Fig4){ref-type="fig"}). The adjusted hazard ratios for target achievement was 0.81 (95% CI 0.61, 1.06; *P* = 0.13) at 6 months and 0.85 (95% CI 0.67, 1.09; *P* = 0.20) at 12 months.Fig. 4Kaplan--Meier curve for HbA1c target attainment within 12 months of index 2

The mean time to therapy intensification was 9.7 months for patients who intensified with a RAI and 23.2 months for those who intensified with a GLP-1 RA (Table [2](#Tab2){ref-type="table"}).Table 2Duration of delay in therapy intensificationCharacteristicIntensified therapyGLP-1 RA (*n* = 77)RAI (*n* = 529)Total intensified (*n* = 606)Delay in intensification, months Mean23.29.711.4 SD24.417.218.8 Median1033 Lower quartile--upper quartile4--411--101--11

Medication Adherence and Persistence {#Sec10}
------------------------------------

Baseline adherence to BI therapy (the PDC in the 180 days prior to index 1) was 73% (SD 23.9%). Adherence to therapy was comparable between intensifiers (71% \[SD 24.2%\]) and non-intensifiers (76% \[SD 23.5%\]; *P* \< 0.0001) at baseline. Patients who intensified therapy with a GLP-1 RA had the greatest adherence to therapy post index 2 (81%; SD 20.7%), whereas those who intensified with a RAI had substantially lower adherence (61%; SD 20.4%). Mean persistence with intensification therapy in the intensifier group was 595.0 days (SD 792.8).

Weight {#Sec11}
------

Mean weight at the latest value during the 12 months after index 2 was 107.7 kg (SD 21.6) and 89.2 kg (SD 20.6) for those who intensified to GLP-1 RA and RAI, respectively, and 91.8 kg (SD 21.2) for those who did not intensify, resulting in mean changes of − 3.1, + 1.2, and + 1.4 kg, respectively.

Discussion {#Sec12}
==========

In our study population, patients with T2D suboptimally controlled on BI and who intensified therapy had greater reductions in HbA1c than those who did not receive intensified therapy (non-intensifiers). Most of this improvement occurred within the first 6 months post intensification. Thus, injectable therapy intensification resulted in clinically meaningful improvements in glycemic control. However, a relatively high proportion of both subgroups of the overall study population (67% of BI intensifiers and 72% of non-intensifiers) did not achieve the target HbA1c after 12 months. This observation, coupled with the high mean baseline HbA1c values and the \> 6-month delay in therapy intensification for many after the first detection of suboptimally controlled HbA1c, suggests that there is still a gap between guideline recommendations \[[@CR7], [@CR8]\] and real-world practice.

These findings are consistent with those reported in other studies conducted in both the USA and Europe. In a study of a large primary care-based population (*n* ≈ 12,000) in the UK, only 31% of eligible patients with T2D  and HbA1c suboptimally controlled with BI (HbA1c ≥ 7.5% \[≥ 58 mmol/mol\]) underwent therapy intensification during the 9-year study period, with a median time to intensification of 3.7 years \[[@CR10]\].

Similar findings were reported by an earlier retrospective analysis of the THIN database that included both patients with controlled and suboptimally controlled T2D who (1) were current BI users and (2) who received a prescription for BI during the period January to June 2006 \[[@CR11]\]. During a mean follow-up of 2.9 years, only 19.3% of patients intensified therapy, whereas 59.8% remained on their initial BI regimen during the entire follow-up period, despite evidence of poor glycemic control (mean HbA1c 8.4% \[69 mmol/mol\] at baseline and 8.1% \[65 mmol/mol\] at the end of follow-up). Patients who underwent intensification had a higher mean HbA1c at baseline (9.2% \[77 mmol/mol\]) but had an HbA1c decrease of 0.6% from baseline to end of follow-up.

In the present study, early reductions in HbA1c were noted in the non-intensifier cohort that were similar to those seen in the intensifier cohort, but only for the first 3 months. This may have been due to dose adjustments and insulin titration, but data on these treatments were not captured in the current study. Importantly, the intensifier cohort continued to show constant and sustained improvement for the period of observation until 12 months. This HbA1c change and target attainment represent a clinically relevant advantage for patients who intensify therapy when contextualized with the results of the UK Prospective Diabetes Study (UKPDS) study \[[@CR4]\], which demonstrated that each 1% reduction in HbA1c corresponded with a 21% risk reduction in diabetes-related deaths, a 14% risk reduction for myocardial infarctions, and a 37% risk reduction for microvascular complications \[[@CR4]\]. More recently, a modeling study estimated 10-year cumulative risk reductions of 5 and 9% for myocardial infarction, 6 and 13% for stroke, 14 and 27% for diabetes-related ulcer, 22 and 39% for amputation, and 14 and 25% for single-eye blindness when HbA1c is at 9% (75 mmol/mol) and 8% (64 mmol/mol), respectively, compared with when HbA1c is at 10% (86 mmol/mol) \[[@CR17]\]. Given that the baseline HbA1c in the current study was approximately 9.4% (79 mmol/mol) and the follow-up HbA1c among intensifiers was approximately 8.6% (70 mmol/mol), this result represents clinically meaningful risk reductions.

The Kaplan--Meier analysis indicates that intensifiers had a numerically higher probability of achieving target HbA1c over time, but that a substantial proportion of the population (67% of BI intensifiers and 72% of non-intensifiers) had not achieved the target at 12 months post intensification. Even with optimal adherence, previous studies have indicated that approximately 40% of patients do not achieve their HbA1c targets with BI \[[@CR18], [@CR19]\]. However, these studies occurred in a clinical trial setting and thus differed in terms of measurement frequency and the selected population. Nevertheless, it is clear that therapy intensification with BI is an inadequate strategy for many patients.

Mean adherence to therapy was somewhat higher at baseline (PDC 73% overall) than post intensification (PDC 63% among intensifiers), at which time it was similar to that reported using US claims data, in which insulin users had a medication possession ratio of 0.63 \[[@CR20]\]. While there are many methods to measure adherence, which vary from study to study, there is a lack of consensus on the best measure of adherence \[[@CR21]\]. Despite this, previous analyses have consistently shown that improved adherence is associated with decreased costs and resource use \[[@CR21]\]. A focused literature review described a wide range of adherence rates in the UK ranging from around 43% to up to 86%, but noted the difficulties in the objective assessment of adherence \[[@CR22]\]. In our study, despite appropriate adherence and persistence with therapies, low proportions of patients achieved the target HbA1c within 6 or 12 months of therapy intensification. Thus, realistically, additional clinically relevant reductions in HbA1c are unlikely to be delivered through further improvement in adherence to therapy, as this is already approaching the upper level of what has been previously reported in the literature.

The persistence with therapy reported in this study is of notably longer duration than persistence reported in the literature. A review of a retrospective database study in the USA \[[@CR23]\] found that patients adding a RAI to their current therapy remained persistent for only 274 days, approximately half the time observed in the present analysis. Additionally, in a further study in the USA, for those using a GLP-1 RA and BI, median persistence was 133 days \[[@CR24]\], which is less than a quarter of the persistence with therapy observed in our study. However, comparisons between European and American persistence data are complicated by access issues around private health insurance and co-payments, differences in electronic health record data capture, and routine health care practices (among other factors).

There are some key limitations to this study. Differences in disease severity may affect comparisons between intensifiers and non-intensifiers, although attempts were made to control for such known confounding variables through matching of patients according to baseline characteristics. Diet, exercise, and lifestyle modifications as recommended to patients could not be taken into account and may have been different between groups. Adherence data were based on prescriptions issued; however, it is not known whether these prescriptions were filled or used as directed. Changes in dose (not analyzed in the study) may have impacted estimations of days' supplied and thus led to over- or underestimations of adherence. Furthermore, adherence was calculated using PDC, which is commonly used in retrospective studies; it is more conservative than other methods such as the medication possession ratio \[[@CR25]\]. Changes in BI dose due to titration or changes in oral anti-diabetes drug background therapy were not captured and may have influenced HbA1c levels. Occult episodes of hypoglycemia, not captured in THIN, may have altered patients' behavior and affected glycemic control and target attainment. While individualized glycemic goals were set for patients who were assessed to be at high and low risk for hypoglycemia, it is possible that these goals did not reflect true individualized treatment goals in some cases. Lastly, the clinical benefits and cost implications of the differences in HbA1c goal achievement between intensifiers and non-intensifiers are outside the scope of the current study.

Conclusions {#Sec13}
===========

Therapy intensification in real-world patients with suboptimally controlled T2D while on BI therapy is associated with HbA1c improvements and an increased likelihood of achieving HbA1c targets. However, many patients do not have their therapy intensified, although this is recommended in the guidelines, or intensification is delayed. In this study, reductions in HbA1c were evident at 6 months following therapy intensification, although with little additional benefit being seen at 12 months. As most of the HbA1c reduction occurred during the 6 months post intensification, this study demonstrates that improvements in glycemic control are achieved rapidly in this population. These results suggest that patients who fail to achieve their glycemic targets at 6 months are unlikely to benefit from continuing on the current therapy and that therapy intensification or change should be promptly considered.
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